An audience with...Joseph Bolen. Interview by Bethan Hughes.
Chief Scientific Officer, Millennium: The Takeda Oncology Company,Cambridge, Massachusetts, USA. Prior to joining Millennium, Joseph Bolen, Ph.d., held positions including Vice President and Global head of Oncologic diseases at hoechst Marion Roussel, and executive director of oncology drug discovery at the Bristol-Myers Squibb Pharmaceutical Research institute. in addition to other senior academic positions, he was Section Chief of the Biochemical Oncology Department at the National Cancer Institute in Maryland, USA, and a founding member of their laboratory of tumor virus biology.
Bolen
Joseph
J
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001897:Boronic Acids / Q000494:pharmacology / Q000627:therapeutic use; D000069286:Bortezomib; D015195:Drug Design; D004345:Drug Industry / Q000458:organization & administration* / Q000639:trends; D006801:Humans; D008495:Medical Oncology / Q000191:economics / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy; D011719:Pyrazines / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib